{
  "session_date": "2026-01-24",
  "methodology": "Web search validation of filtered novel predictions",
  "validated_predictions": [
    {
      "drug": "Naproxen",
      "disease": "Type 2 Diabetes",
      "score": 0.989,
      "validation_status": "FALSE_POSITIVE",
      "evidence": {
        "summary": "Naproxen showed 'no significant influence on fasting glucose levels' in diabetics",
        "related_finding": "Salsalate (different NSAID) showed 0.53% A1c reduction, but naproxen did not",
        "concern": "NSAIDs increase cardiovascular risk in diabetics (JACC 2023)"
      },
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC1401608/",
        "https://www.jacc.org/doi/10.1016/j.jacc.2023.02.026"
      ],
      "actionability": "NONE - no evidence of benefit, potential harm"
    },
    {
      "drug": "Linsitinib",
      "disease": "Breast Cancer",
      "score": 0.972,
      "validation_status": "FALSE_POSITIVE",
      "evidence": {
        "summary": "Phase III trials with IGF-1R inhibitors FAILED in breast cancer",
        "mechanism": "Could overcome tamoxifen resistance in ER+ breast cancer in preclinical models",
        "key_finding": "TNBC: 'did not block tumour formation and had no effect on tumour growth in vivo'"
      },
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC7065127/",
        "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0282512"
      ],
      "actionability": "NONE - clinical trials failed"
    },
    {
      "drug": "DL-alpha-Tocopherol (Vitamin E)",
      "disease": "Breast Cancer",
      "score": 0.977,
      "validation_status": "FALSE_POSITIVE",
      "evidence": {
        "summary": "Large-scale clinical trials showed inconsistent/disappointing results",
        "meta_analysis": "No significant association between vitamin E consumption and breast cancer risk",
        "key_insight": "γ-tocopherol and δ-tocopherol may be more effective than α-tocopherol"
      },
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/36963866/",
        "https://link.springer.com/article/10.1186/s12916-022-02366-5"
      ],
      "actionability": "NONE - clinical evidence does not support"
    },
    {
      "drug": "Volociximab",
      "disease": "Multiple Sclerosis",
      "score": 0.962,
      "validation_status": "FALSE_POSITIVE",
      "evidence": {
        "summary": "Never tested for MS - all clinical trials were in oncology (ovarian, renal cancer)",
        "mechanism": "Anti-α5β1 integrin antibody with anti-angiogenic properties",
        "key_finding": "No autoimmune/MS applications ever studied"
      },
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/21276608/",
        "https://clinicaltrials.gov/study/NCT00782093"
      ],
      "actionability": "NONE - mechanism not relevant to MS"
    },
    {
      "drug": "Gemfibrozil",
      "disease": "Heart Failure",
      "score": 0.977,
      "validation_status": "RESEARCH_SUPPORTED",
      "evidence": {
        "summary": "Preclinical evidence shows cardioprotective effects via sGC activation",
        "mechanism": "Pharmacological preconditioning preserves cardiac function after heart transplant in rat models",
        "key_finding": "Improved LV contractility, reduced nitro-oxidative stress and apoptosis",
        "historical": "Helsinki Heart Study showed coronary heart disease prevention"
      },
      "sources": [
        "https://www.nature.com/articles/s41598-017-14587-3",
        "https://www.nejm.org/doi/full/10.1056/nejm198711123172001"
      ],
      "actionability": "MEDIUM - preclinical support, could warrant clinical investigation"
    },
    {
      "drug": "Umeclidinium",
      "disease": "COPD",
      "score": 0.972,
      "validation_status": "ALREADY_USED",
      "evidence": {
        "summary": "Already FDA-approved for COPD as monotherapy and in combinations",
        "note": "Approved in Trelegy Ellipta (triple therapy) and as Incruse Ellipta"
      },
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC5406010/",
        "https://www.nejm.org/doi/full/10.1056/NEJMoa1713901"
      ],
      "actionability": "NONE - already standard of care (ground truth gap)"
    },
    {
      "drug": "Pergolide",
      "disease": "Hypertension",
      "score": 0.987,
      "validation_status": "MECHANISTICALLY_VALID_BUT_WITHDRAWN",
      "evidence": {
        "summary": "Potent antihypertensive effects via dopamine receptor activation confirmed",
        "mechanism": "Central dopamine receptor stimulation + presynaptic inhibition of norepinephrine",
        "preclinical": "Lowered BP in spontaneously hypertensive rats, DOCA-salt models",
        "CRITICAL": "WITHDRAWN FROM US MARKET (2007) due to cardiac valve regurgitation risk"
      },
      "sources": [
        "https://www.sciencedirect.com/science/article/abs/pii/002432057990287X",
        "https://pubmed.ncbi.nlm.nih.gov/12035871/"
      ],
      "actionability": "NONE - drug withdrawn due to safety concerns"
    },
    {
      "drug": "Lovastatin",
      "disease": "Multiple Myeloma",
      "score": 0.964,
      "validation_status": "CLINICAL_TRIAL_SUPPORTED",
      "evidence": {
        "summary": "RCT showed greater progression-free survival with lovastatin + thalidomide/dex",
        "population_study": "SEER-Medicare: 45.6% of MM patients used statins, associated with reduced mortality",
        "mechanism": "t(4;14) MM cells sensitive to lovastatin-induced apoptosis",
        "2024_review": "Cancer Reports recognizes statins as repurposed anti-cancer agents"
      },
      "sources": [
        "https://www.sciencedirect.com/science/article/abs/pii/S2152265020303372",
        "https://onlinelibrary.wiley.com/doi/full/10.1002/cnr2.2078",
        "https://aacrjournals.org/mct/article/6/6/1886/235978/Determinants-of-sensitivity-to-lovastatin-induced"
      ],
      "actionability": "HIGH - existing clinical trial evidence supports use"
    }
  ],
  "summary": {
    "total_validated": 8,
    "clinical_trial_supported": 1,
    "research_supported": 1,
    "already_used": 1,
    "mechanistically_valid_but_withdrawn": 1,
    "false_positives": 4,
    "precision_this_session": "25% (2/8 actionable)",
    "key_discovery": "Lovastatin → Multiple Myeloma has RCT evidence for improved PFS"
  },
  "new_filter_recommendations": [
    {
      "pattern": "Withdrawn drugs",
      "examples": ["Pergolide (cardiac valve risk)", "Cisapride", "Rofecoxib"],
      "action": "Add withdrawn drug list to confidence filter"
    },
    {
      "pattern": "Already FDA-approved for the indication",
      "examples": ["Umeclidinium → COPD", "Natalizumab → MS"],
      "action": "Cross-reference with FDA approval database"
    },
    {
      "pattern": "Failed Phase III trials",
      "examples": ["Linsitinib → breast cancer (IGF-1R inhibitors failed)"],
      "action": "Check clinical trial failure databases"
    }
  ]
}
